<DOC>
	<DOC>NCT01659736</DOC>
	<brief_summary>This study is investigating a new indication of Transcranial Magnetic Stimulation (TMS) by conducting a pilot randomized-controlled trial (RCT) comparing structural neuronavigation-directed TMS to Sham-TMS Placebo therapy for treatment of Generalized Anxiety Disorder (GAD).</brief_summary>
	<brief_title>Transcranial Magnetic Stimulation Treatment for Generalized Anxiety Disorder</brief_title>
	<detailed_description>Participants will complete structural MRI for neuronavigation. Participants will be randomly assigned to treatment condition. TMS or Sham-TMS sessions will occur daily 5 days/week for 6 weeks. Assessments will occur at pretreatment, weekly during treatment, post-treatment, and 3 month.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<criteria>Diagnosed with GAD as the principal or coprincipal disorder Clinical Global Impression Score ≥ 4 Hamilton Anxiety Rating Scale ≥ 18 Hamilton Rating Scale for Depression ≤ 17 Fluency in English Capacity to understand the nature of the study and willingness to sign informed consent form. History of epilepsy or head trauma (LOC &gt; 5 minutes) within the past 6 months. Lifetime history of increased intracranial pressure, seizure disorder, stroke, brain tumor, multiple sclerosis, or brain surgery. A review of patient medications by the study physician indicates an increased risk of seizure. An active autoimmune, endocrine, viral, or vascular disorder affecting the brain; any unstable cardiac disease; hypertension; or severe renal or liver insufficiency. Substance use disorder or PTSD within the past 6 months. Lifetime bipolar disorder, obsessivecompulsive disorder (OCD), psychotic disorder, mental retardation, or pervasive developmental disorder. Any psychotic features, including dementia or delirium. Concurrent psychotherapy and unwillingness to discontinue Medication change within past 3 months. Current serious suicidal or homicidal ideation, and/or serious suicidal attempt within past 6 months. Serious, unstable, or terminal medical condition or clinically judged too psychiatrically unstable to participate in the study. Any contraindication for participation in MRI scan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>